NCT02359695

Brief Summary

The objective of this study is to assess whether a low dose of GH supplementation (0.5 IU/day) increases clinical pregnancy rates in women with a history of POR who failed to become pregnant in two previous IVF cycles.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Oct 2013

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2013

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

February 5, 2015

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 10, 2015

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2017

Completed
Last Updated

May 10, 2017

Status Verified

May 1, 2017

Enrollment Period

3.2 years

First QC Date

February 5, 2015

Last Update Submit

May 9, 2017

Conditions

Keywords

Poor ovarian responseIVFGrowth hormone

Outcome Measures

Primary Outcomes (1)

  • Clinical pregnancy rate

    Presence of an intrauterine gestational sac with embryonic cardiac activity display, evaluated by ultrasound

    7 weeks of gestation

Secondary Outcomes (4)

  • Retrieved oocytes

    On egg retrieval day

  • Number of obtained embryos

    3 days after egg retrieval

  • Embryo quality

    3 days after embryo transfer

  • Proportion of cycles with embryo transfer

    3 days after egg retrieval

Study Arms (1)

GH cycle

EXPERIMENTAL

Subsequent IVF cycle, supplemented with a low dose of growth hormone.

Drug: Growth Hormone

Interventions

A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration

Also known as: Somatotropin
GH cycle

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Women with a history of POR, defined according to the Bologna criteria
  • Absence of pregnancy in at least two previous IVF cycles

You may not qualify if:

  • Body mass index ≥ 30 kg/m2
  • Presence of endocrinopathies
  • Altered karyotype in one or both partners
  • History of invasive ovarian surgery
  • History of chronic, autoimmune or metabolic diseases
  • Altered meiosis in testicular biopsy or altered sperm-FISH
  • Drug therapy in the male partner
  • Participation, within the previous 6 months, in another clinical trial with medication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centro de Infertilidad y Reproducción Humana (CIRH)

Barcelona, 08017, Spain

Location

MeSH Terms

Conditions

Infertility

Interventions

Growth Hormone

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

Pituitary Hormones, AnteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and Proteins

Study Officials

  • Mario Brassesco, MD

    Centro de Infertilidad y Reproducción Humana

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 5, 2015

First Posted

February 10, 2015

Study Start

October 1, 2013

Primary Completion

December 1, 2016

Study Completion

May 1, 2017

Last Updated

May 10, 2017

Record last verified: 2017-05

Locations